Online inquiry

IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12638MR)

This product GTTS-WQ12638MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RSPO3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_032784.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84870
UniProt ID Q9BXY4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12638MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6642MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ15818MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1943MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ6105MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7601MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ2565MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ879MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ10998MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW